Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?

Radiotherapy and Oncology

Volumn 91, Issue 3, 2009, Pages 399-404

  Abramyuk, Andrij ^a   Tokalov, Sergey ^a   Zöphel, Klaus ^b   Koch, Arne ^a   Szluha Lazanyi, Kornelia ^a   Gillham, Charles ^c   Herrmann, Thomas ^b   Abolmaali, Nasreddin ^a  

^a Helmholtz Zentrum Dresden Rossendorf   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Academic Unit of Clinical and Molecular Oncology   (Ireland)

Author keywords

FDG PET CT; Non small cell lung cancer; Radiotherapy planning

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RELAPSE; CANCER RISK; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METABOLIC REGULATION; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; TISSUE STRUCTURE; TREATMENT FAILURE; TUMOR VOLUME; VOLUMETRY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 65649142624     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.01.003     Document Type: Article

References (37)

1. Choy H., Nabid A., Stea B., et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5918-5928
2. Rengan R., Rosenzweig K.E., Venkatraman E., et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 741-747
3. Rosenzweig K.E., Fox J.L., Yorke E., et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 103 (2005) 2118-2127
4. Sura S., Yorke E., Jackson A., and Rosenzweig K.E. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer J 13 (2007) 238-242
5. Sura S., Gupta V., Yorke E., Jackson A., Amols H., and Rosenzweig K.E. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87 (2008) 17-23
6. Christian J.A., Bedford J.L., Webb S., and Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67 (2007) 735-741
7. Daisne J.F., Sibomana M., Bol A., Doumont T., Lonneux M., and Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 69 (2003) 247-250
8. Daisne J.F., and Gregoire V. Multimodalities imaging for target volume definition in radiotherapy. Bull Cancer 93 (2006) 1175-1182
9. Nestle U., Kremp S., and Grosu A.L. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81 (2006) 209-225
10. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
11. Sura S., Greco C., Gelblum D., Yorke E.D., Jackson A., and Rosenzweig K.E. (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1397-1402
12. Kim Y., and Tome W.A. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 66 (2006) 1528-1542
13. Gillies R.J., Raghunand N., Karczmar G.S., and Bhujwalla Z.M. MRI of the tumor microenvironment. J Magn Reson Imaging 16 (2002) 430-450
14. Poetzsch C., Hofheinz F., and van den Hoff J. Fast user guided segmentation and quantification of volume in 3-d datasets. Mol Imaging Biol 7 (2005) 152
15. WHO handbook for reporting results of cancer treatment. Offset Publication No. 48. Geneva (Switzerland): World Health Organization. 1979.
16. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
17. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
18. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1016-1023
19. van Baardwijk A., Bosmans G., Boersma L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68 (2007) 771-778
20. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
21. Gregoire V., Haustermans K., Geets X., Roels S., and Lonneux M. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med 48 Suppl 1 (2007) 68S-77S
22. Van de Steene J., Linthout N., de Mey J., et al. Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol 62 (2002) 37-49
23. Langen K.M., and Jones D.T. Organ motion and its management. Int J Radiat Oncol Biol Phys 50 (2001) 265-278
24. Ponisch F., Richter C., Just U., and Enghardt W. Attenuation correction of four dimensional (4D) PET using phase-correlated 4D-computed tomography. Phys Med Biol 53 (2008) N259-268
25. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
26. Thorwarth D., Eschmann S.M., Scheiderbauer J., Paulsen F., and Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5 (2005) 152
27. Chapman J.D., Bradley J.D., Eary J.F., et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 55 (2003) 294-301
28. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance. Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
29. van Baardwijk A., Bosmans G., Dekker A., et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82 (2007) 145-152
30. Schutze C., Bergmann R., Yaromina A., et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 83 (2007) 311-315
31. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung cancer 55 (2007) 79-87
32. Sasaki R., Komaki R., Macapinlac H., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
33. Burgman P., Odonoghue J.A., Humm J.L., and Ling C.C. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med 42 (2001) 170-175
34. Klopp A.H., Chang J.Y., Tucker S.L., et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69 (2007) 1409-1416
35. Pandit N., Gonen M., Krug L., and Larson S.M. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30 (2003) 78-84
36. Davies A., Tan C., Paschalides C., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung cancer 55 (2007) 75-78
37. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 60 (2004) 1272-1282